Reagent Red Blood Cells

1 of 4
INTERNATIONAL
Not all products are approved in all regions.

ITEM DESCRIPTION PACKAGE

Two-vial set consisting of one vial each of A1 and B cells used
AFFIRMAGEN® to detect expected ABO blood group antibodies in patient
2 x 10 mL
Reagent Red Blood Cells and donor samples. AFFIRMAGEN® cells are resuspended in
EDTA diluent to prevent hemolysis in reverse grouping.
Four-vial set consisting of one vial each of A1, A2, B, and
group O cells used to detect expected ABO blood group
AFFIRMAGEN® 4
antibodies in patient and donor samples. AFFIRMAGEN® cells 4 x 10 mL
Reagent Red Blood Cells
are resuspended in EDTA diluent to prevent hemolysis in
reverse grouping.
A set of 2 cells for antibody screening. Special lots available
to meet your additional antigen requirements, including HLA
SELECTOGEN®
(Bg) negative cells. A monoclonal HLA antibody with Class I 2 x 10 mL
Reagent Red Blood Cells
antigen specificity is used to screen all cells to minimize Bg/
HLA antibody reactivity.
A set of 3 cells for antibody screening. Ideal for group (type)
and screen procedures. Cells provided are homozygous
for RH, Fya, Fyb, Jka, Jkb, M, and S antigens, giving you the
SURGISCREEN®
confidence you require to detect significant antibodies, 3 x 10 mL
Reagent Red Blood Cells
including HLA (Bg) negative cells. A monoclonal HLA
antibody with Class I antigen specificity is used to screen all
cells to minimize Bg/HLA antibody reactivity.
ORTHO® Coombs Cells sensitized with lgG for maximal detection of a false
1 x 10 mL
Control Cells negative antiglobulin test.
ORTHO® BRC Set is supplied as 3 separate control sera and
5 separate control red blood cells. ORTHO® BRC Set contains
control sera for examining reagent red blood cells used in the
laboratory for the reactivity of their antigens during their shelf
life and control red cells for testing blood grouping reagents
for reactivity and specificity. The control sera are prepared
ORTHO® BRC 1 Set
from defibrinated, heat-inactivated plasma of selected
donors and contain 0.1% sodium azide as a preservative. The
control red blood cells are 3% suspensions of red blood cells
from selected donors in a modified Alsever’s solution which
contains 0.01% neomycin and 0.33% chloramphenicol as
antibacterial additives.

A complete system for “problem” antibodies

ITEM DESCRIPTION PACKAGE
An 11-cell primary panel that provides homozygosity of all
ORTHO RESOLVE® Panel A major blood group antigens, allowing for the identification of cells
Reagent Red Blood Cells frequently encountered single antibody specificities and many 11 x 3 mL
multiple antibody combinations.
An 11-cell panel to use in concert with ORTHO RESOLVE® Panel
ORTHO RESOLVE® Panel B cells
A to identify more difficult antibody combinations. It can also
Reagent Red Blood Cells 11 x 2 mL
serve as an excellent source of selected cells.
Kit includes: A combination of two 11-cell panels (one
untreated and one ficin-treated) that allows the technologist treated cells
to more clearly identify weak reacting antibodies and separate 11 x 3 mL
mixtures of antibodies when they are directed against
ORTHO RESOLVE® Panel C
enzyme-sensitive antigens. Ficin-treated red cells assist in
Reagent Red Blood Cells
the identification of antibodies in 2 ways: the enhancement of
reactivity of some antigen/antibody reactions such as those untreated cells
associated with the RH or Kidd System and by destroying or 11 x 3 mL
altering antigens such as M, N, Fya, Fyb, and S.

Please consult full product Instructions for Use.

 2 of 4

0.8% Reagent Red Blood Cells for ORTHO BioVue® System

0.8% Reagent Red Blood Cells are prediluted at manufacturing with a specially formulated resuspension
solution to an optimal concentration for use without further modification in the ORTHO BioVue® System.
This solution delivers a low ionic strength environment to enhance antibody reactivity and eliminates the
need for a separate reagent.

0.8% Red Cell Diluent resuspending solution is a low ionic diluent used to prepare 0.8% suspensions for
autocontrol and crossmatch testing.

ITEM DESCRIPTION PACKAGE

Two vials of pooled human red blood cells in a 0.8%
suspension: one vial of group A1 cells, one vial of group B
cells. They are used in reverse (serum/plasma) grouping to
confirm the presence or absence of anti-A and anti-B in the
0.8% AFFIRMAGEN® sera being tested.
2 x 10 mL
Reagent Red Blood Cells
The cells are D (RH1) negative to prevent agglutination
should the most common unexpected antibody, anti-D (RH1)
be present. EDTA is added to prevent hemolysis due to
complement-binding ABO antibodies.
Four vials of pooled human red blood cells in a 0.8%
suspension: one vial containing A1 cells, one vial containing A2
cells, one vial containing B cells, and one vial containing O cells.
They are used in reverse (serum/plasma) grouping to confirm
the presence or absence of anti-A1, anti-A2, anti-B, and O cells
0.8% AFFIRMAGEN® 4
in the sera being tested. 4 x 10 mL
Reagent Red Blood Cells
The cells are D (RH1) negative to prevent agglutination
should the most common unexpected antibody, anti-D (RH1)
be present. EDTA is added to prevent hemolysis due to
complement-binding ABO antibodies.
Two vials of human red blood cells, which have been typed
for most clinically significant antigens, as well as some rare
antigens. The Rh phenotype of 0.8% SELECTOGEN® I is R1R1
and 0.8% SELECTOGEN® II is R2R2. The product is used to
0.8% SELECTOGEN® detect unexpected blood group antibodies in patient or
2 x 10 mL
Reagent Red Blood Cells donor serum. The product is screened to provide cells with
homozygous expression of RH-hr antigens (C, c, E, e), Fy(a+b-),
and Jk(a+b-). A monoclonal HLA antibody with Class I antigen
specificity is used to screen all cells to minimize Bg/HLA
antibody reactivity.
A set of 3 individual group O red blood cells. Cells provided are
homozygous for RH, Fya, Fyb, Jka, Jkb, M, and S antigens, giving
you the confidence you require to detect significant antibodies,
0.8% SURGISCREEN® including HLA (Bg) negative cells. The antigenic characteristics
3 x 10 mL
Reagent Red Blood Cells of this product provide a sensitive antibody-screening test,
ideal for use in the type and screen procedure. A monoclonal
HLA antibody with Class I antigen specificity is used to screen
all cells to minimize Bg/HLA antibody reactivity.

Please consult full product Instructions for Use.

 3 of 4

0.8% Reagent Red Blood Cells for ORTHO BioVue® System, cont.
ITEM DESCRIPTION PACKAGE
A set of 3 individual group O red blood cells that are in the
format of untreated and ficin treated. Cells provided are
homozygous for RH, Fya, Fyb, Jka, Jkb, M, and S antigens, giving
0.8% ORTHO BioVue® Screen
you the confidence you require to detect significant antibodies, 6 x 10 mL
Reagent Red Blood Cells
including HLA (Bg) negative cells. The antigen characteristics
of this product provide a sensitive antibody screening test,
ideal for use in the type and screen procedure.
An 11-cell panel that provides a selection of cells to assure
0.8% ORTHO RESOLVE® identification of antibodies to common blood group factors
Panel A Reagent Red including those known to exhibit dosage. This selection of cells 11 x 3 mL
Blood Cells allows for the identification of frequently encountered single
antibody specificities and most multiple antibody combinations.
Designed to complement 0.8% ORTHO RESOLVE® Panel A
and to serve as a selected cell panel. 0.8% ORTHO RESOLVE®
0.8% ORTHO RESOLVE®
Panel B allows for the identification of more difficult antibody
Panel B Reagent Red 11 x 3 mL
combinations by providing specially selected cells. The
Blood Cells
presence of an RzR1 and a Cellano negative cell is assured on
every panel.
Two 11-cell panels; one is untreated and the other, consisting
of the same cells, is ficin treated. Ficin-treated red cells assist treated cells
in the identification of antibodies in 2 ways: the enhancement 11 x 3 mL
of reactivity of some antigen/antibody reactions such as those
0.8% ORTHO RESOLVE®
associated with the RH or Kidd System and by destroying or
Panel C Reagent Red
altering antigens such as M, N, Fya, Fyb, and S. Using both the
Blood Cells
treated and untreated panels allows the technologist to more
clearly identify weak reacting antibodies, as well as separate untreated cells
mixtures of antibodies when they are directed against enzyme- 11 x 3 mL
sensitive antigens.

Please consult full product Instructions for Use.

 4 of 4

Reagent Red Blood Cells designed for ORTHO BioVue® System

Qualitative tests to detect expected blood group antibodies for confirmation of ABO forward (red cell)
grouping and for the detection of atypical blood group antibodies in the ORTHO BioVue® System for
in vitro diagnostic use.

ITEM DESCRIPTION PACKAGE

Two-vial set consisting of one vial each of A1 and B cells used
AFFIRMAGEN® to detect expected ABO blood group antibodies in patient and
2 x 3 mL
Reagent Red Blood Cells donor samples. AFFIRMAGEN® cells are resuspended in EDTA
diluent to prevent hemolysis in reverse grouping.
Four-vial set consisting of one vial each of A1, A2, B and
group O cells used to detect expected ABO blood group
AFFIRMAGEN® 4
antibodies in patient and donor samples. AFFIRMAGEN® cells 4 x 3 mL
Reagent Red Blood Cells
are resuspended in EDTA diluent to prevent hemolysis in
reverse grouping.
Two vials of human red blood cells, which have been typed
for most clinically significant antigens, as well as some
rare antigens. The RH phenotype of SELECTOGEN® I is
R1R1 and SELECTOGEN® II is R 2R 2. The product is used to
SELECTOGEN® detect unexpected blood group antibodies in patient or
2 x 3 mL
Reagent Red Blood Cells donor serum. The product is screened to provide cells
with homozygous expression of RH-hr antigens (C, c, E, e),
Fy(a+b-), and Jk(a+b-). A monoclonal HLA antibody with
Class I antigen specificity is used to screen all cells to
minimize Bg/HLA antibody reactivity.
A set of 3 cells for antibody screening. Ideal for group (type)
and screen procedures. Cells provided are homozygous
for RH, Fya, Fyb, Jka, Jkb, M, and S antigens, giving you the
SURGISCREEN®
confidence you require to detect significant antibodies, 3 x 3 mL
Reagent Red Blood Cells
including HLA (Bg) negative cells. A monoclonal HLA
antibody with Class I antigen specificity is used to screen all
cells to minimize Bg/HLA antibody reactivity.
A set of 3 individual group O red blood cells that are in the
format of untreated and ficin treated. Cells provided are
homozygous for RH, Fya, Fyb, Jka, Jkb, M, and S antigens, giving
ORTHO BioVue® Screen
you the confidence you require to detect significant antibodies, 6 x 2 mL
Reagent Red Blood Cells
including HLA (Bg) negative cells. The antigen characteristics
of this product provide a sensitive antibody screening test,
ideal for use in the type and screen procedure.

NOTE: Information valid as of August 6, 2015. This product listing is periodically updated/refreshed. If you
have questions, please contact the Technical Solutions Center at www.orthoclinical.com.

Please consult full product Instructions for Use.

All trademarks are the property of Ortho-Clinical Diagnostics, Inc.

©Ortho-Clinical Diagnostics, Inc. 2015 PR-00063